Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy

Haematologica. 2008 Nov;93(11):1758-60. doi: 10.3324/haematol.13265. Epub 2008 Sep 11.

Authors

Ester M Orlandi, Fausto Baldanti, Annalisa Citro, Lara Pochintesta, Marta Gatti, Mario Lazzarino

PMID: 18790800
DOI: 10.3324/haematol.13265

No abstract available

Publication types

Letter

MeSH terms

Alemtuzumab
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / administration & dosage
Cytomegalovirus Infections / complications
Cytomegalovirus Infections / diagnosis*
Diagnosis, Differential
Disease Progression
Epstein-Barr Virus Infections / complications
Epstein-Barr Virus Infections / diagnosis*
Female
Genome, Viral
Herpesvirus 4, Human / genetics
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Middle Aged
Monitoring, Physiologic / methods
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Alemtuzumab
Cyclophosphamide
Vidarabine
fludarabine